Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Nov 21;13:1684096. doi: 10.3389/fbioe.2025.1684096

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2025 Kao, Fan, Ro-Lin Chang, Chen, Yen, Sufian, Yang and Chen.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Diagram illustrating a three-step process for treating genetic deficiencies in a fetus: 1. Detection of diseases using genetic analysis. 2. Preparation of therapeutic cells, including autologous stem cells needing gene correction and allogeneic stem cells. 3. Ultrasound-guided delivery of cells into the fetus. — In utero stem cell therapy. The central concept of in utero stem cell therapy is built upon the recognition of congenital anomalies present in the fetus, succeeded by the ex vivo rectification of the genetic abnormalities in either autologous or allogeneic stem cells, culminating in the ultrasound-mediated delivery of the corrected stem cells into the fetus to ensure normal developmental processes. This intervention also possesses the capacity to condition the fetal immune system, thereby augmenting immune tolerance.